203 related articles for article (PubMed ID: 14742761)
1. Warfarin initiation and monitoring with clotting factors II, VII, and X.
Trask AS; Gosselin RC; Diaz JA; Dager WE
Ann Pharmacother; 2004 Feb; 38(2):251-6. PubMed ID: 14742761
[TBL] [Abstract][Full Text] [Related]
2. Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination.
Bijsterveld NR; Middeldorp S; Berends F; Büller HR
J Thromb Thrombolysis; 2000 Apr; 9(3):263-9. PubMed ID: 10728026
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy.
Costa IM; Serralheiro AI; Rodrigues M; Alves G; Falcão AC
Biomed Pharmacother; 2010 Feb; 64(2):130-2. PubMed ID: 20045627
[TBL] [Abstract][Full Text] [Related]
4. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
5. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
Shapiro NL; Durr EA; Krueger CD
Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
[TBL] [Abstract][Full Text] [Related]
6. Minimal Prolongation of Prothrombin Time with Extended Exposure to Argatroban.
McAlister RK; Ito S
Pharmacotherapy; 2015 Jul; 35(7):e122-6. PubMed ID: 26147471
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin-induced thrombocytopenia in a child.
Dager WE; White RH
Ann Pharmacother; 2004 Feb; 38(2):247-50. PubMed ID: 14742760
[TBL] [Abstract][Full Text] [Related]
8. Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation.
Dager WE; Gosselin RC; Yoshikawa R; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):598-601. PubMed ID: 14982973
[TBL] [Abstract][Full Text] [Related]
9. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.
Makris M; Greaves M; Phillips WS; Kitchen S; Rosendaal FR; Preston EF
Thromb Haemost; 1997 Mar; 77(3):477-80. PubMed ID: 9065997
[TBL] [Abstract][Full Text] [Related]
10. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
11. Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.
Baumann Kreuziger LM; Datta YH; Johnson AD; Zantek ND; Shanley R; Reding MT
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):232-6. PubMed ID: 24681704
[TBL] [Abstract][Full Text] [Related]
12. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.
Perry SL; Samsa GP; Ortel TL
Thromb Haemost; 2005 Dec; 94(6):1196-202. PubMed ID: 16411394
[TBL] [Abstract][Full Text] [Related]
13. Factor VII levels and international normalized ratios in the early phase of warfarin therapy.
Benzon HT; Avram MJ; Benzon HA; Kirby-Nolan M; Nader A
Anesthesiology; 2010 Feb; 112(2):298-304. PubMed ID: 20098130
[TBL] [Abstract][Full Text] [Related]
14. Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio.
Christensen TD; Jensen C; Larsen TB; Christiansen K; Sørensen B
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):358-65. PubMed ID: 19417631
[TBL] [Abstract][Full Text] [Related]
15. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.
Limdi NA; Nolin TD; Booth SL; Centi A; Marques MB; Crowley MR; Allon M; Beasley TM
Am J Kidney Dis; 2015 May; 65(5):701-9. PubMed ID: 25468385
[TBL] [Abstract][Full Text] [Related]
16. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Jeske WP; Walenga JM
Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
[TBL] [Abstract][Full Text] [Related]
18. Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase.
Weinstock DM; Chang P; Aronson DL; Kessler CM
Am J Hematol; 1998 Mar; 57(3):193-9. PubMed ID: 9495368
[TBL] [Abstract][Full Text] [Related]
19. Lepirudin-induced thrombocytopenia following subcutaneous administration.
Schroeder WS; Tran MT; Gandhi PJ
Am J Health Syst Pharm; 2009 May; 66(9):834-7. PubMed ID: 19386946
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome.
Efthymiou M; Lawrie AS; Mackie I; Arachchillage D; Lane PJ; Machin S; Cohen H
Thromb Res; 2015 Jun; 135(6):1191-7. PubMed ID: 25895847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
